Important differences in the metabolism of CSE inhibitors;Wichtige unterschiede im metabolismus von CSE-hemmern

Internist

Volumn 40, Issue 2, 1999, Pages 235-236

  Feuring, M ^a   Wehling, Martin ^a  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450; ERYTHROMYCIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

DRUG METABOLISM; ENZYME INHIBITION; HUMAN; SHORT SURVEY;

ANTICHOLESTEREMIC AGENTS; BIOTRANSFORMATION; DRUG INTERACTIONS; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 0032929116     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050328     Document Type: Short Survey

References (12)

1. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH (1991) Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 19:740-748
2. Garnett WR (1995) Interactions with hydroxymethyl-glutaryl-coenzyme A reductase inhibitors. Am J Health Systems Pharm 52:1639-1645
3. Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, Bokelman DL (1989) Animal safety and toxicology of simvastatin and related hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Med 87:28S-38S
4. Halstenson CE, Triscari J, DeVault AR, Shapiro B, Keane W, Pan H (1992) Single dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 32:124-132
5. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26-37
6. Jones CD (1996) Lipitor™ (Atorvastatin calcium tablets). Clinical and biopharmaceutics review. FDA document NDA20-702:1-39
7. Kantola T, Kari T, Kivistö KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65
8. Muck W, Ochmann K, Rohde G, Unger S, Kuhlmann J (1998) Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 53:469-473
9. Neuvonen PJ, Jalava MD (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60:54-61
10. Neuvonen PJ, Kantola T, Kivistö KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 62:332-341
11. Quion JAV, Jones PH (1994) Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 27:94-103
12. Ritter W, Oehmann K, Mück W, Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Arch Pharmacol 355 (Suppl):R127